These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 15191451)
41. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS. Andrade A; Wildemeersch D Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571 [TBL] [Abstract][Full Text] [Related]
42. The levonorgestrel intrauterine system in nulliparous women. Prager S; Darney PD Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602 [TBL] [Abstract][Full Text] [Related]
43. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Bahamondes MV; Hidalgo MM; Bahamondes L; Monteiro I Contraception; 2011 Nov; 84(5):e11-6. PubMed ID: 22018132 [TBL] [Abstract][Full Text] [Related]
44. A pilot study on the acceptability of levonorgestrel-releasing intrauterine device by young, single, nulliparous Chinese females following surgical abortion. Li CF; Lee SS; Pun TC Contraception; 2004 Mar; 69(3):247-50. PubMed ID: 14969674 [TBL] [Abstract][Full Text] [Related]
45. [Clinical study of levonorgestrel-releasing intrauterine system for adenomyosis]. He SM; Zhang YD Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec; 26(12):1794-6. PubMed ID: 17259122 [TBL] [Abstract][Full Text] [Related]
46. [Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis]. Deng S; Lang JH; Leng JH; Liu ZF; Sun DW; Zhu L Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):664-8. PubMed ID: 17199919 [TBL] [Abstract][Full Text] [Related]
47. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221 [TBL] [Abstract][Full Text] [Related]
48. Long-term use of the levonorgestrel-releasing intrauterine system. Inki P Contraception; 2007 Jun; 75(6 Suppl):S161-6. PubMed ID: 17531611 [TBL] [Abstract][Full Text] [Related]
49. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV. Heikinheimo O; Lehtovirta P; Suni J; Paavonen J Hum Reprod; 2006 Nov; 21(11):2857-61. PubMed ID: 16880227 [TBL] [Abstract][Full Text] [Related]
50. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg. Teunissen AM; Merry AHH; Devies IEC; Roumen FJME Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):449-456. PubMed ID: 31696740 [No Abstract] [Full Text] [Related]
51. Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Heikinheimo O; Inki P; Schmelter T; Gemzell-Danielsson K Hum Reprod; 2014 Jun; 29(6):1182-8. PubMed ID: 24682613 [TBL] [Abstract][Full Text] [Related]
52. Is there a role for use of levonorgestrel intrauterine system in women with chronic pelvic pain? Anpalagan A; Condous G J Minim Invasive Gynecol; 2008; 15(6):663-6. PubMed ID: 18774757 [TBL] [Abstract][Full Text] [Related]
53. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age. Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570 [TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. Brown PM; Farquhar CM; Lethaby A; Sadler LC; Johnson NP BJOG; 2006 Jul; 113(7):797-803. PubMed ID: 16827763 [TBL] [Abstract][Full Text] [Related]
55. Progestin-releasing intrauterine systems and leiomyoma. Kaunitz AM Contraception; 2007 Jun; 75(6 Suppl):S130-3. PubMed ID: 17531604 [TBL] [Abstract][Full Text] [Related]
56. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Sheng J; Zhang WY; Zhang JP; Lu D Contraception; 2009 Mar; 79(3):189-93. PubMed ID: 19185671 [TBL] [Abstract][Full Text] [Related]
57. Bleeding patterns with the levonorgestrel-releasing intrauterine system when used for heavy menstrual bleeding in women without structural pelvic pathology: a pooled analysis of randomized controlled studies. Jensen J; Mansour D; Lukkari-Lax E; Inki P; Burock K; Fraser IS Contraception; 2013 Jan; 87(1):107-12. PubMed ID: 23040140 [TBL] [Abstract][Full Text] [Related]
58. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy. Bourdrez P; Bongers MY; Mol BW Fertil Steril; 2004 Jul; 82(1):160-6, quiz 265. PubMed ID: 15237006 [TBL] [Abstract][Full Text] [Related]
59. Pregnancy in a patient with a displaced levonorgestrel-releasing intrauterine system: a case report. Budiman H; Kümper C; Mylonas I; Thaler CJ; Friese K; Weissenbacher ER Arch Gynecol Obstet; 2007 Sep; 276(3):263-4. PubMed ID: 17356827 [TBL] [Abstract][Full Text] [Related]
60. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device. Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]